Deals In Depth: December 2017
Executive Summary
In a billion-dollar alliance, Roivant Sciences got exclusive rights to HanAll's neonatal Fc receptor-targeting antibody for autoimmune diseases. CVS is hoping to improve health care delivery and costs with the $77 billion acquisition of insurer Aetna. Financing in both the biopharma and devices industries was down from last month.